CONGRESS PRESENTATIONS
IDWeekTM 2025
Infectious Disease Week
Atlanta, Georgia
October 19-22, 2025
-
ViiV-Sponsored Data
-
Cabotegravir Prevention
Barnett S, et al.
Screening Practices for HIV and Sexually Transmitted Infections During Cabotegravir Long Acting or Daily Oral Pre-Exposure Prophylaxis Use in the US
Glick JL, et al.
Associations between Intersectional Stigma and Long-Acting Injectable PrEP (LAI-PrEP) Willingness and Preference among Gay, Bisexual, and other Men who have Sex with Men (GBMSM)
Islek D, et al.
Characteristics associated with HIV pre-exposure prophylaxis persistence among men who have sex with men in the United States: results from the American Men’s Internet Survey (AMIS) 2023-24
Metzner AA, et al.
Human Immunodeficiency Virus (HIV) Testing and Evidence of HIV among Real-World Long-Acting Pre-Exposure Prophylaxis (PrEP) Users in a United States Claims Database: Results from the PrEPFACTS Study
Nelson KL, et al.
Black Women’s Experiences on Long-Acting Cabotegravir for PrEP: Interim Patient Findings from the EBONI Study
-
Cabotegravir Treatment
Henry Z, et al.
PREFER-LA: People with HIV (PWH) in the United States with Prior Adherence Challenges with Oral Antiretroviral Therapy (ART) Prefer Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) Therapy after Switch
Sension MG, et al.
Few differences in persistence and virologic outcomes across age groups among CAB+RPV LA users: Findings from the OPERA Cohort
Short WR, et al.
PREFER-LA: Improved Adherence and Viral Control in Real-World Study of People with HIV (PWH) in the United States with Adherence Challenges on Oral Antiretroviral Therapy (ART) Switching to Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA)
-
Cabotegravir Treatment and Prevention
-
Dolutegravir-based Regimens
Boulos J, et al.
Real-world Effectiveness and Safety Outcomes in People with HIV-1 Switching to Dolutegravir + Lamivudine (DTG + 3TC) with Unknown Prior Genotype: a Systematic Literature Review and Meta-analysis
Fraysse J, et al.
The Global REGAL cohort: A REtrospective real-world study of the effectiveness and tolerability of the antiretroviral treatment reGimens DTG/3TC compAred to BIC/FTC/TAF in older persons Living with HIV
Ogbuagu O, et al.
The US REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV
Yan L, et al.
Polypharmacy, drug-drug interactions, and risk of hospitalization among veterans with HIV taking 2-, 3-, and 4-drug antiretroviral therapy regimens
-
Pipeline
-
-
ViiV-Supported & Collaborative Data
-
Cabotegravir Prevention
Hardy WD, et al.
Patient-reported Outcomes of Long-Acting Injectable Cabotegravir Versus Oral PrEP Use for HIV Prevention: Sub-analysis of the AURORA study
Hardy WD, et al.
Real-world Persistence to Long-acting Cabotegravir Versus Oral PrEP for HIV Prevention in Participants Using a Digital Health Companion Tool (AURORA Study)
-
Cabotegravir Treatment
Berg KA, et al.
Using Participatory Design to Establish A Workflow for Administration of Long-Acting Cabotegravir + Rilpivirine in Community Pharmacies
Dieterich M, et al.
Acceptability, Feasibility and Appropriateness of the Mobile Outreach Retention and Engagement (MORE) Program and Home Long-Acting Cabotegravir/Rilpivirine (CAB+RPV LA) Injections for People with HIV (PWH) Experiencing Adherence Challenges at Whitman-Walker Health in Washington D.C.
Epps PV, et al.
Veterans on Cabotegravir-Rilpivirine Long Acting Treatment for HIV are Younger and More Urban Than Those Who Continue Oral ART
Meyer JP, et al.
Preliminary experience using a pharmacist-led intervention to support injectable HIV treatment for women with health-related social needs
Nkodo ENE, et al.
Beyond Distance: Social Barriers Influence Long-acting Antiretrovirals Location Preference Among People with HIV in Rural Areas
Shon A, et al.
Safety and Effectiveness of Long-Acting Cabotegravir/Rilpivirine in People with HIV and Severe Renal Impairment
-
Dolutegravir-based Regimens
-
Fostemsavir
-
